A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Voyage
Definium Therapeutics US, Inc.
200 participants
Dec 11, 2024
INTERVENTIONAL
Conditions
Summary
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
Eligibility
Inclusion Criteria3
- Diagnosis of GAD per DSM-5
- Male or female aged 18 to 74
- HAM-A Total Score ≥20
Exclusion Criteria4
- Certain psychiatric disorders (other than generalized anxiety disorder)
- First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
- Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
- Any clinically significant unstable illness
Interventions
A substance that is designed to have no therapeutic value
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Locations(36)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06741228